Neoadjuvant cisplatin and radical cesarean hysterectomy for cervical cancer in pregnancy.
BACKGROUND
A 28-year-old Hispanic gravida 1 was found to have a 4-5 cm cervical mass when she presented at 23 weeks gestation. On pelvic examination, the tumor was shown to encompass the entire circumference of the cervix without parametrial or vaginal involvement. A biopsy of the mass revealed a poorly differentiated squamous-cell carcinoma of the cervix. An MRI study of the abdomen and pelvis showed a 4 cm cervical mass that was suspicious for left parametrial and rectovaginal septal involvement. No hydronephrosis or lymphadenopathy was noted. The patient elected to proceed with her pregnancy.


METHODS
General physical and gynecological examinations, cervical biopsy, pelvic and obstetric ultrasound, histopathological examination, MRI of the abdomen and pelvis without and with gadolinium, neonatal hearing test and renal function studies.


METHODS
Poorly differentiated stage IB2 squamous-cell carcinoma of the cervix with MRI imaging suggestive of parametrial and rectovaginal septal involvement.


RESULTS
Neoadjuvant chemotherapy using weekly cisplatin from 24 to 30 weeks, bed rest and oral terbutaline at 31 weeks because of premature contractions, and a course of antenatal steroids to promote fetal lung maturity. At 33 weeks radical cesarean hysterectomy, bilateral pelvic and para-aortic lymphadenectomy and bilateral ovarian transposition were carried out, followed by adjuvant pelvic radiation therapy with cisplatin chemosensitization 4 weeks postpartum.
Karam
Amer
A
UCLA/Cedars-Sinai Gynecologic Oncology fellowship program, Los Angeles, CA, USA.
Feldman
Nancy
N
Holschneider
Christine H
CH
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D002585:Cesarean Section; D002945:Cisplatin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007044:Hysterectomy; D020360:Neoadjuvant Therapy; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000628:therapy*; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000628:therapy*
D000970:Antineoplastic Agents; D002945:Cisplatin